ЭНДРЮС, Стивен В. (US),КОЛАКОВСКИ, Габриэлль Р. (US),ДОУБЕЛ, Роберт К. (US),НАНДА, Ниша (US),БАЙЛЕНКЕР, Джош Х. (US),БЛЕЙК, Джеймс Ф. (US),БРЭНДХУБЕР, Барбара Дж. (US),ЧЖАО, Цюинь (US)
申请号：
RU2018118967
公开号：
RU2018118967A
申请日:
2016.10.26
申请国别(地区):
RU
年份:
2019
代理人:
摘要：
Provided herein are methods of treating a subject having a cancer, methods of selecting a treatment for a subject having a cancer, methods of selecting a subject having a cancer for a treatment that does not include a Trk inhibitor, methods of determining the likelihood that a subject having a cancer will have a positive response to a treatment with a Trk inhibitor, methods of predicting the efficacy of a Trk inhibitor in a subject having cancer, methods of determining a subject's risk for developing a Trk inhibitor-resistant cancer, and methods of determining the presence of a Trk inhibitor-resistant cancer in a subject, based on the detection of a cell from a sample from the subject that has at least one of the the point mutations in NTRK1 and/or NTRK2 and/or NTRK3.
